China Bio Profit Falls 33% Despite 10% Revenue Gain

Adjusted Profit Jumps 31.4% Despite Net Income Plunge

China Biopharmaceutical (01177.HK) reported divergent top and bottom-line results for its 2025 fiscal year. While revenue grew a healthy 10.3% to RMB 31.834 billion, profit attributable to shareholders plummeted 33% to RMB 2.343 billion. This headline profit decline raises questions about the company's cost structure and one-off expenses during the period.

However, the company's management highlighted a stronger underlying performance by pointing to its basic profit, an adjusted figure that excludes discontinued operations and certain non-cash items. This metric showed robust health, increasing 31.4% year-over-year to RMB 4.541 billion. The significant gap between reported and adjusted profit suggests that non-operational or non-recurring charges heavily impacted the final net income figure, a critical point for investors to analyze in the firm's detailed disclosures.

Innovation Revenue Nears 48% of Sales on R&D Push

A key driver of the company's top-line growth was its successful pivot towards innovative drugs. Revenue from this segment expanded by 26.2% to RMB 15.22 billion, now accounting for 47.8% of the company's total revenue. This strategic shift indicates a move towards higher-margin products and reduced reliance on generic pharmaceuticals, positioning the company for more sustainable long-term growth.

This strategic focus is supported by a substantial research and development budget. China Biopharmaceutical invested RMB 6.317 billion in R&D, equivalent to 19.8% of its total revenue. This high level of investment is essential for maintaining a competitive pipeline in the fast-evolving pharmaceutical industry, though it also represents a significant and ongoing cost center that pressures near-term profitability.

Dividend Hike to HKD 0.05 Signals Management Confidence

Despite the steep drop in reported net profit, China Biopharmaceutical's board signaled a confident outlook by increasing its shareholder payout. The company declared a final dividend of HKD 0.05 per share, up from the HKD 0.04 distributed in the same period last year. This brings the total dividend for the fiscal year to HKD 0.10 per share.

This decision to raise the dividend suggests that management views the factors that dragged down net profit as temporary or non-core to the business's cash-generating capabilities. For shareholders, the increased payout provides a tangible return and serves as a vote of confidence in the company's future earnings power, especially as other firms in China's biopharma sector report mixed results.